Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

In the recently published study in The Lancet, first-authored by Dr. Sue Ann Costa Clemens from the University of Oxford in the United Kingdom and the University of Siena in Italy, a comprehensive analysis has been pursued on the immunogenicity and safety of both homologous and heterologous boosting after receiving the inactivated vaccine CoronaVac.

26 Jan 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.

26 Jan 2022

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

In a new study, researchers evaluated SARS-CoV-2 vaccination-induced T cell responses cross-recognition among the early and novel SARS-CoV-2 variants.

26 Jan 2022

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

In a new study, a team of researchers explored the association between total immunoglobulin (IgM, IgA, and IgG) against SARS-CoV-2 and protective immunity.

26 Jan 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

An interdisciplinary team of researchers from Europe analyzed the alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients.

26 Jan 2022

The Role of Glycans in the Cell and Glycans Imaging Method

In this interview, News-Medical talks to a pioneer of glycan imaging, Richard Drake about glycans, their role in maintaining cellular homeostasis, glycopeptide analysis, and method development for glycan imaging.

From Bruker Daltonics 26 Jan 2022

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

In a new study, scientists have compared the Omicron variant with the Delta VOC (B.1.617.2) as well as the wildtype strain (B.1), with respect to their interaction with the antiviral type 1 interferon response in infected cells.

26 Jan 2022

Effects of the Omicron spike amino acid changes in the interaction with human ACE2 receptor or human antibodies

A recent study analyzed the effects of the interaction between SARS-CoV-2 Omicron spike amino acid and the human ACE2 receptor or with human antibodies.

26 Jan 2022

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

In a new study, researchers have been investigating the effects of megadoses of corticosteroids on hospitalized COVID-19 patients.

26 Jan 2022

Beta-amyloid deposits found in young patients with COVID-19

A new study describes the finding that patients of COVID-19 exhibit large amounts of focal β-amyloid deposits in their neocortical tissues.

25 Jan 2022

Heterologous vaccine schedule provides extraordinary response to third dose of coronavirus vaccines

A third, booster dose of either the ChAdOx1 nCoV-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), AD26.COV2-S (Janssen) or CoronaVac (SinoVac) coronavirus vaccine induce a significant increase in antibody levels in those who have previously received two doses of CoronaVac.

25 Jan 2022

Antibody News and Research

Further Reading

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

The Role of Glycans in the Cell and Glycans Imaging Method

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

Effects of the Omicron spike amino acid changes in the interaction with human ACE2 receptor or human antibodies

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

Beta-amyloid deposits found in young patients with COVID-19

Heterologous vaccine schedule provides extraordinary response to third dose of coronavirus vaccines

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Humoral correlate of protection for SARS-CoV-2 may reduce COVID-19 infection risk

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo